1. Hiraoka, A., Ohashi, Y., Okamoto, S., et al., Japanese FK506 BMT (Bone Marrow Transplantation) Study Group: Phase III Study Comparing Tacrolimus (FK506) with Cyclosporine for Graft-versus-Host Disease Prophylaxis after Allogeneic Bone Marrow Transplantation, Bone Marrow Transplant., 2001, vol. 28, no. 2, pp.181–185.
2. Niwa, Y., Terashima, T., and Sumi, H., Topical Application of the Immunosuppressant Tacrolimus Accelerates Carcinogenesis in Mouse Skin, Br. J. Dermatol., 2003, vol. 149, no. 5, pp. 960–967.
3. Choi, S.J., You, H.S., and Chung, S.Y., Tacrolimus-Induced Apoptotic Signal Transduction Pathway, Transplant. Proc., 2008, vol. 40, no. 8, pp. 2734–2736.
4. Sommerer, C., Giese, T., Meuer, S., and Zeier, M., New Concepts to Individualize Calcineurin Inhibitor Therapy in Renal Allograft Recipients, Saudi J. Kidney Dis. Transplant., 2010, vol. 21, no. 6, pp. 1030–1037.
5. Li, H., Rao, A., and Hogan, P.G., Interaction of Calcineurin with Substrates and Targeting Proteins, Trends Cell Biol., 2011, vol. 21, no. 2, pp. 91–103.